HC Wainwright Estimates Sanara MedTech FY2024 Earnings

Sanara MedTech Inc. (NASDAQ:SMTI) – HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Sanara MedTech in a note issued to investors on Monday, December 23rd. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of ($1.24) per share for the year. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for Sanara MedTech’s Q4 2024 earnings at ($0.28) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.96) EPS.

Sanara MedTech Stock Down 2.1 %

Shares of SMTI opened at $34.20 on Wednesday. The stock has a market capitalization of $298.94 million, a price-to-earnings ratio of -34.55 and a beta of 1.57. Sanara MedTech has a 52 week low of $26.00 and a 52 week high of $43.25. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23. The stock has a fifty day moving average of $34.82 and a 200-day moving average of $32.25.

Sanara MedTech (NASDAQ:SMTI) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.28. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. The business had revenue of $21.67 million during the quarter. During the same quarter in the prior year, the company earned ($0.13) earnings per share.

Hedge Funds Weigh In On Sanara MedTech

Several large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in shares of Sanara MedTech by 127.2% during the third quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock valued at $123,000 after acquiring an additional 2,272 shares during the last quarter. Geode Capital Management LLC raised its position in Sanara MedTech by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock worth $2,670,000 after purchasing an additional 3,755 shares during the last quarter. Barclays PLC lifted its holdings in Sanara MedTech by 323.0% during the 3rd quarter. Barclays PLC now owns 5,731 shares of the company’s stock worth $174,000 after buying an additional 4,376 shares during the period. Finally, State Street Corp lifted its holdings in Sanara MedTech by 9.2% during the 3rd quarter. State Street Corp now owns 58,688 shares of the company’s stock worth $1,775,000 after buying an additional 4,932 shares during the period. 8.10% of the stock is currently owned by institutional investors.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.